LGR5 분자 정보
Molecule Name
Leucine-rich repeat-containing G-protein coupled receptor 5
분자 별명
LGR5, GPR49, GPR67, G-protein coupled receptor 49, G-protein coupled receptor 67, G-protein coupled receptor HG38, Leucine-rich repeat-containing G-protein coupled receptor 5
Drug Development Progress
임상 약물 수2
시판 약물 수0
최고 연구 개발 단계Phase 2 Clinical
표적 별명
FEX，G Protein-Coupled Receptor 49，GRP49，HG38，G-protein coupled receptor HG38，GPR49，GPR67，G-protein coupled receptor 49，Leucine-rich repeat-containing G-protein coupled receptor 5，LGR5，Leucine Rich Repeat Containing G Protein-Coupled Receptor 5，G-Protein Coupled Receptor 67，Orphan G Protein-Coupled Receptor HG38
분자 배경
LGR5 (also known as GPR49) is a seven-transmembrane protein of the class A Rhodopsin-like family of GPCRs. LGR5 and LGR4 bind the R-spondins with high affinity and mediate the potentiation of Wnt/β-catenin signaling by enhancing Wnt-induced LRP6 phosphorylation. The LGR5/RSPO complex could promote Wnt signalling via the neutralization of two transmembrane E3 ligases, RNF43 and ZNRF3.
LGR5 제품 목록
You Have Viewed 0 Of 0 Results
임상 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Petosemtamab | MCLA-158 | Phase 2 Clinical | Merus Nv | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | 상세 |
| CNA-3103 | CNA-3103 | Phase 2 Clinical | Carina Biotech Pty Ltd | Colorectal Neoplasms | 상세 |